Volpara promotes study on stratifying breast cancer risk
Breast imaging software developer Volpara Solutions is highlighting a study...Read more on AuntMinnie.comRelated Reading: Volpara software awarded certification Volpara expands GE distribution agreement globally Volpara to launch updated mammo decision support at ECR Volpara gets FDA nod for new density uses ScreenPoint partners with Volpara
Publication date: Available online 17 June 2019Source: MethodsAuthor(s): Yuexu Jiang, Duolin Wang, Dong Xu, Trupti JoshiAbstractNowadays, large amounts of omics data have been generated and contributed to increasing knowledge about associated biological mechanisms. A new challenge coming along is how to identify the active pathways and extract useful insights from these data with huge background information and noise. Although biologically meaningful modules can often be detected by many existing informatics tools, it is still hard to interpret or make use of the results towards in silico hypothesis generation and testing....
New J. Chem., 2019, Accepted Manuscript DOI: 10.1039/C9NJ01834D, PaperMin Zheng, Yong-Jin Cao, Wei-Hua Cai, Xi Shi, Mou-Feng Wang, Yu-Jie Deng A potentiometric immunoassay based on copper(II) ion-selective electrode (Cu-ISE) was designed for the quantitative determination of carbohydrate antigen 15-3 (CA 15-3; a tumor marker associated with breast cancer). To construct... The content of this RSS Feed (c) The Royal Society of Chemistry
[Cameroon Tribune] A campaign for free testing scheduled from the 10-13 at Mbingo Baptist Hospital Bonaberi.
Abstract Breast cancer, one of the leading causes of death in women in the United States, challenges therapeutic success in patients due to tumor heterogeneity, treatment resistance, metastasis and disease recurrence. Knowledge of immune system involvement in normal breast development and breast cancer has led to extensive research into the immune landscape of breast cancer and multiple immunotherapy clinical trials in breast cancer patients. However, poor immunogenicity and T-cell infiltration along with heightened immunosuppression in the tumor microenvironment have been identified as potential challenges to the...
Condition: Breast Cancer Intervention: Diagnostic Test: Mammography outside official screening Sponsors: Tartu University Hospital; University of Tartu; North Estonia Medical Centre Recruiting
Condition: HER2-Negative Breast Cancer Intervention: Drug: Pembrolizumab Sponsors: University of Malaya; Merck Sharp & Dohme (MSD); National University Hospital, Singapore; Clinical Research Malaysia Not yet recruiting
Condition: HER2-positive Early Breast Cancer Interventions: Drug: SIBP-01; Drug: Herceptin; Drug: Docetaxel; Drug: Carboplatin Sponsors: Shanghai Institute Of Biological Products; Fudan University Recruiting
Condition: Breast Cancer Interventions: Procedure: IR Imaging; Procedure: 3D Scanning Sponsor: University of Texas Southwestern Medical Center Not yet recruiting
We report the application of RNA sequencing technology for high-throughput profiling of mRNA expression in breast cancer cell line